Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours

European Journal of Endocrinology

Volumn 150, Issue 3, 2004, Pages 345-349

  Zacharieva, Sabina ^a   Atanassova, Iliana ^b   Orbetzova, Maria ^b   Nachev, Emil ^b   Kalinov, Krassimir ^a   Kirilov, Gregory ^b   Shigarminova, Rositza ^b   Ivanova, Radina ^b   Dashev, Georgy ^b  

^a NEW BULGARIAN UNIVERSITY   (Bulgaria)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN E2; RENIN; VASCULOTROPIN;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL TUMOR; ADULT; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHING SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE ACTION; HUMAN; IMMUNORADIOMETRIC ASSAY; MALE; MALIGNANT NEOPLASTIC DISEASE; PHEOCHROMOCYTOMA; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; URINARY EXCRETION;

ADRENAL GLAND NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; CUSHING SYNDROME; DINOPROSTONE; FEMALE; HUMANS; HYPERALDOSTERONISM; MALE; PHEOCHROMOCYTOMA; RENIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1842526937     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500345     Document Type: Article

References (26)

1. Ferrara N & Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Reviews 1997 18 4-25.
2. Ferrara N, Winer J, Burton T, Rowland A, Siegel M, Phillips HS et al. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. Journal of Clinical Investigation 1993 91 160-170.
3. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996 77 858-863.
4. Pai R, Szabo IL, Soreghan BA, Atay S, Kawanaka H & Tarnawski AS. PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochemical and Biophysical Research Communications 2001 286 923-928.
5. Chiarugi V, Magnelli L & Gallo O. Cox-2, iNOS and p53 as playmakers of tumor angiogenesis (review). International Journal of Molecular Medicine 1998 2 715-719.
6. Saijonmaa O, Nyman T, Kosonen R & Fyhrquist F. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. American Journal of Physiology - Heart and Circulatory Physiology 2001 280 H885-H891.
7. Pupilli C, Lasagni L, Romagnani P, Bellini F, Manneli M, Misciglia N et al. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. Journal of the American Society of Nephrology 1999 10 245-255.
8. Sasaki K, Murohara T, Ikeda H, Sugaya T, Shimada T, Shintani S et al. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. Journal of Clinical Investigation 2002 109 603-611.
9. Heikkila P, Arola J, Voutilainen R, Salmenkivi K, Kahri AI & Liu J. Expression of vascular endothelial growth factor in human adrenal. Endocrine Research 2000 26 867-871.
10. Kolomecki K, Stepien H, Bartos M & Kuzdak K. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocrine Regulation 2001 35 9-16.
11. Bernini GP, Moretti A, Bonadio AG, Menicagli M, Viacava P, Naccarato AC et al. Angiogenesis in human normal and pathologic adrenal cortex. Journal of Clinical Endocrinology and Metabolism 2002 87 4961-4965.
12. Jyung RW, Le Clair EE, Bernat RA, Kang TS, Ung F, McKenna MJ et al. Expression of angiogenic growth factors in paragangliomas. Laryngoscope 2000 110 161-167.
13. Zielke A, Middeke M, Hoffmann S, Colombo-Benkmann M, Barth P, Hassan I et al. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery 2002 132 1056-1063.
14. Favier J, Plouin PF, Corvol P & Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas: Distinctive traits in malignant tumors. American Journal of Pathology 2002 161 1235-1246.
15. Salmenkivi K, Heikkila P, Liu J, Haglund C & Arola J. VEGF in 105 pheochromocytomas: Enhanced expression correlates with malignant outcome. Acta Pathologica, Microbiologica et Immunologica Scandinavica 2003 111 458-464.
16. De Fraipont F, El Atifi M, Gicquel C, Bertagna X, Chambaz EM & Feige J. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: Correlation with genotypic alterations. Journal of Clinical Endocrinology and Metabolism 2000 85 4734-4741.
17. Ljungberg B, Jacobsen J, Haggstrom-Rudolfssson S, Rasmuson T, Lindh G & Grankvist K. Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma. Urological Research 2003 31 335-340.
18. Fosslien E. Review: Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Annals of Clinical and Laboratory Science 2001 31 325-348.
19. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. Clinical Investigation 2003 112 67-73.
20. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Tsujinoue H et al. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. International Journal of Oncology 2002 20 1227-1231.
21. Takeshita S, Tomiyama H, Yokoyama N, Kawamura Y, Furukawa T & Ishigai Y et al. Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats. Cardiovascular Research 2001 52 314-320.
22. Fabre J-E, Rivard A, Magner M, Silver M & Isner JM. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999 99 3043-3049.
23. Tenschert W, Baumgart P, Greminger P, Vetter W & Vetter H. Pathogenetic aspects of hypertension in Cushing's syndrome. Cardiology 1985 72 (Suppl 1) 84-90.
24. Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K & Senba S. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1986 62 275-279.
25. Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG & Lip GY. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. American Journal of Hypertension 2003 16 11-20.
26. Felmeden DC, Spencer CG, Blann AD, Beevers DG & Lip GY. Physical activity in relation to indices of endothelial function and angiogenesis factors in hypertension: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Journal of Internal Medicine 2003 253 81-91.